{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:07:33Z","timestamp":1777421253170,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11822-x","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:15Z","timestamp":1777374975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation CD179a-CAR-T cells demonstrate potent and sustained anti-tumor activity in preclinical B-cell malignancies"],"prefix":"10.1007","volume":"53","author":[{"given":"Hoda Mohamed","family":"Elessawey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gehan","family":"Safwat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7391-9550","authenticated-orcid":false,"given":"Rania Hassan","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdy M.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6646-4674","authenticated-orcid":false,"given":"Nashwa","family":"El-khazragy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"11822_CR1","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y (2022) CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front Immunol 13:927153. https:\/\/doi.org\/10.3389\/fimmu.2022.927153","journal-title":"Front Immunol"},{"issue":"1","key":"11822_CR2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12935-024-03479-y","volume":"24","author":"S Mansoori","year":"2024","unstructured":"Mansoori S, Noei A, Maali A, Seyed-Motahari SS, Sharifzadeh Z (2024) Recent updates on allogeneic CAR-T cells in hematological malignancies. Cancer Cell Int 24(1):304. https:\/\/doi.org\/10.1186\/s12935-024-03479-y","journal-title":"Cancer Cell Int"},{"issue":"6","key":"11822_CR3","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3324\/haematol.2023.283848","volume":"109","author":"BLZ Oh","year":"2024","unstructured":"Oh BLZ, Vinanica N, Wong DMH, Campana D (2024) Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia. Haematologica 109(6):1677\u20131688. https:\/\/doi.org\/10.3324\/haematol.2023.283848","journal-title":"Haematologica"},{"issue":"8","key":"11822_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J (2021) Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 384(8):705\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"issue":"8","key":"11822_CR5","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3390\/cancers16081599","volume":"16","author":"P Bl\u00fcm","year":"2024","unstructured":"Bl\u00fcm P, Kayser S (2024) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations. Cancers 16(8):1599. https:\/\/doi.org\/10.3390\/cancers16081599","journal-title":"Cancers"},{"issue":"1","key":"11822_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","volume":"13","author":"DP Wong","year":"2022","unstructured":"Wong DP, Roy NK, Zhang K, Anukanth A, Asthana A, Shirkey-Son NJ, Dunmire S, Jones BJ, Lahr WS, Webber BR, Moriarity BS, Caimi P, Parameswaran R (2022) A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun 13(1):217. https:\/\/doi.org\/10.1038\/s41467-021-27853-w","journal-title":"Nat Commun"},{"issue":"1","key":"11822_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-024-01568-z","volume":"17","author":"R Zheng","year":"2024","unstructured":"Zheng R, Zhu X, Xiao Y (2024) Advances in CAR-T-cell therapy in T-cell malignancies. J Hematol Oncol 17(1):49. https:\/\/doi.org\/10.1186\/s13045-024-01568-z","journal-title":"J Hematol Oncol"},{"issue":"1","key":"11822_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, J\u00e4ger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak \u00d6, Salles G, Maziarz RT, Investigators J (2019) Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"issue":"10450","key":"11822_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","volume":"404","author":"MJ Frank","year":"2024","unstructured":"Frank MJ, Baird JH, Kramer AM, Srinagesh HK, Patel S, Brown AK, Oak JS, Younes SF, Natkunam Y, Hamilton MP, Su Y-J, Agarwal N, Chinnasamy H, Egeler E, Mavroukakis S, Feldman SA, Sahaf B, Mackall CL, Muffly L, Miklos DB, Klysz DD, Gkitsas-Long N, Bacigalupi J, Iglesias M, Crawford E, Nichols L, Cunanan K, Tamaresis J, Spiegel JY, Ehlinger Z, Kuo A, Reynolds WD, Arai S, Johnston L, Lowsky R, Meyer E, Negrin RS, Rezvani AR, Shiraz P, Sidana S, Weng WK, Bharadwaj S, Dahiya S, Smith M, Schultz LM, Ramakrishna S, Davis KL, Tunuguntla R (2024) CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet 404(10450):353\u2013363. https:\/\/doi.org\/10.1016\/S0140-6736(24)00746-3","journal-title":"Lancet"},{"key":"11822_CR10","doi-asserted-by":"publisher","first-page":"107327482412637","DOI":"10.1177\/10732748241263713","volume":"31","author":"MB Ali","year":"2024","unstructured":"Ali MB (2024) Recent Advances in CAR-T Therapy. Cancer Control 31:10732748241263713. https:\/\/doi.org\/10.1177\/10732748241263713","journal-title":"Cancer Control"},{"issue":"18","key":"11822_CR11","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2217\/imt-2020-0181","volume":"12","author":"N El-Khazragy","year":"2020","unstructured":"El-Khazragy N, Ghozy S, Emad P, Mourad M, Razza D, Farouk YK, Mohamed NA, Ahmed MK, Youssef T, Bahnasawy YM, Elmasery S (2020) Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies. Immunotherapy 12(18):1341\u20131357. https:\/\/doi.org\/10.2217\/imt-2020-0181","journal-title":"Immunotherapy"},{"issue":"12","key":"11822_CR12","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1016\/j.febslet.2010.04.057","volume":"584","author":"I-L M\u00e5rtensson","year":"2010","unstructured":"M\u00e5rtensson I-L, Almqvist N, Grimsholm O, Bernardi AI (2010) The pre-B cell receptor checkpoint. FEBS Lett 584(12):2572\u20132579. https:\/\/doi.org\/10.1016\/j.febslet.2010.04.057","journal-title":"FEBS Lett"},{"issue":"2","key":"11822_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1182\/bloodadvances.2021005245","volume":"6","author":"SS Winter","year":"2022","unstructured":"Winter SS, McCaustland A, Qu C, Simeona Ne, Heerema NA, Carroll AJ, Wood BL, Gheorghe G, Mullighan CG, Wilson BS (2022) VpreB surrogate light chain expression in B-lineage ALL: a report from the Children\u2019s Oncology Group. Blood Adv 6(2):585\u2013589. https:\/\/doi.org\/10.1182\/bloodadvances.2021005245","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"11822_CR14","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood-2024-199853","volume":"144","author":"P Gordon","year":"2024","unstructured":"Gordon P, Williams R, Ostergaard J, Muretta J, Wilson BS, Lambert L, Singleton TP, Tasian SK, Winter SS (2024) A Novel Antibody-Drug Conjugate Targeting the CD179a Component of the Surrogate Light Chain for the Treatment of B-Cell Acute Lymphoblastic Leukemia\/Lymphoma. Blood 144(Supplement 1):1407\u20131407. https:\/\/doi.org\/10.1182\/blood-2024-199853","journal-title":"Blood"},{"issue":"1","key":"11822_CR15","doi-asserted-by":"publisher","first-page":"e0245349","DOI":"10.1371\/journal.pone.0245349","volume":"16","author":"M Khaled","year":"2021","unstructured":"Khaled M, Moustafa AS, El-Khazragy N, Ahmed MI, Abd Elkhalek MA, El Salahy EM (2021) CRISPR\/Cas9 mediated knock-out of VPREB1 gene induces a cytotoxic effect in myeloma cells. PLoS ONE 16(1):e0245349. https:\/\/doi.org\/10.1371\/journal.pone.0245349","journal-title":"PLoS ONE"},{"key":"11822_CR16","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.csbj.2024.02.018","volume":"23","author":"D Rosati","year":"2024","unstructured":"Rosati D, Palmieri M, Brunelli G, Morrione A, Iannelli F, Frullanti E, Giordano A (2024) Differential gene expression analysis pipelines and bioinformatic tools for the identification of specific biomarkers: A review. Comput Struct Biotechnol J 23:1154\u20131168. https:\/\/doi.org\/10.1016\/j.csbj.2024.02.018","journal-title":"Comput Struct Biotechnol J"},{"key":"11822_CR17","doi-asserted-by":"publisher","unstructured":"Mohanty R, Manoswini M, Dhal AK, Ganguly N (2022) In silico analysis of a novel protein in CAR T-cell therapy for the treatment of hematologic cancer through molecular modelling, docking, a nd dynamics approach. Comput Biol Med 151. https:\/\/doi.org\/10.1016\/j.compbiomed.2022.106285. (Pt A):106285","DOI":"10.1016\/j.compbiomed.2022.106285"},{"key":"11822_CR18","doi-asserted-by":"publisher","first-page":"849363","DOI":"10.3389\/fmolb.2022.849363","volume":"9","author":"AN Prybutok","year":"2022","unstructured":"Prybutok AN, Yu JS, Leonard JN, Bagheri N (2022) Mapping CAR T-Cell Design Space Using Agent-Based Models. Front Mol Biosci 9:849363. https:\/\/doi.org\/10.3389\/fmolb.2022.849363","journal-title":"Front Mol Biosci"},{"issue":"7","key":"11822_CR19","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1080\/09168451.2016.1156482","volume":"80","author":"G Yusakul","year":"2016","unstructured":"Yusakul G, Sakamoto S, Pongkitwitoon B, Tanaka H, Morimoto S (2016) Effect of linker length between variable domains of single-chain variable fragment antibody against daidzin on its reactivity. Biosci Biotechnol Biochem 80(7):1306\u20131312. https:\/\/doi.org\/10.1080\/09168451.2016.1156482","journal-title":"Biosci Biotechnol Biochem"},{"issue":"11","key":"11822_CR20","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang L, Pan S, Wei X, Xu X, Wei Q (2023) Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development. Mol Ther 31(11):3146\u20133162. https:\/\/doi.org\/10.1016\/j.ymthe.2023.09.021","journal-title":"Mol Ther"},{"issue":"6","key":"11822_CR21","doi-asserted-by":"publisher","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","volume":"18","author":"T Asmamaw Dejenie","year":"2022","unstructured":"Asmamaw Dejenie T, Tiruneh GMM, Dessie Terefe G, Tadele Admasu F, Wale Tesega W, Chekol Abebe E (2022) Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum vaccines immunotherapeutics 18(6):2114254. https:\/\/doi.org\/10.1080\/21645515.2022.2114254","journal-title":"Hum vaccines immunotherapeutics"},{"key":"11822_CR22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3389\/fmicb.2018.00895","volume":"9","author":"Y Ohmine","year":"2018","unstructured":"Ohmine Y, Kiyokawa K, Yunoki K, Yamamoto S, Moriguchi K, Suzuki K (2018) Successful Transfer of a Model T-DNA Plasmid to E. coli Revealed Its Dependence on Recipient RecA and the Preference of VirD2 Relaxase for Eukaryotes Rather Than Bacteria as Recipients. Front Microbiol 9:895. https:\/\/doi.org\/10.3389\/fmicb.2018.00895","journal-title":"Front Microbiol"},{"key":"11822_CR23","doi-asserted-by":"publisher","unstructured":"Martinez M, Reif R, Pappas D (2010) Detection of apoptosis: A review of conventional and novel techniques. Anal Methods - ANAL METHODS 2(8). https:\/\/doi.org\/10.1039\/c0ay00247j","DOI":"10.1039\/c0ay00247j"},{"key":"11822_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101318","author":"X Bubnova","year":"2025","unstructured":"Bubnova X, Hope L, Wheadon H (2025) Evaluation of current mouse in vivo models and advanced in vitro models for leukaemia research. Blood Reviews:101318. https:\/\/doi.org\/10.1016\/j.blre.2025.101318","journal-title":"Blood Reviews:101318"},{"issue":"1","key":"11822_CR25","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1097\/pai.0000000000000370","volume":"25","author":"SM Seyed Jafari","year":"2017","unstructured":"Seyed Jafari SM, Hunger RE (2017) IHC Optical Density Score: A New Practical Method for Quantitative Immunohistochemistry Image Analysis. Appl Immunohistochem Mol morphology: AIMM 25(1):e12\u2013e13. https:\/\/doi.org\/10.1097\/pai.0000000000000370","journal-title":"Appl Immunohistochem Mol morphology: AIMM"},{"issue":"2\u20133","key":"11822_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mcp.2011.03.001","volume":"25","author":"HM Amer","year":"2011","unstructured":"Amer HM, Almajhdi FN (2011) Development of a SYBR Green I-based real-time RT-PCR assay for detection and quantification of bovine coronavirus. Mol Cell Probes 25(2\u20133):101\u2013107. https:\/\/doi.org\/10.1016\/j.mcp.2011.03.001","journal-title":"Mol Cell Probes"},{"issue":"26","key":"11822_CR27","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","volume":"127","author":"JH Park","year":"2016","unstructured":"Park JH, Geyer MB, Brentjens RJ (2016) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 127(26):3312\u20133320. https:\/\/doi.org\/10.1182\/blood-2016-02-629063","journal-title":"Blood"},{"issue":"1","key":"11822_CR28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1186\/s12885-024-12651-6","volume":"24","author":"E Montagna","year":"2024","unstructured":"Montagna E, de Campos NSP, Porto VA, da Silva GCP, Suarez ER (2024) CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient\u2019s age, and tumor types. BMC Cancer 24(1):1037. https:\/\/doi.org\/10.1186\/s12885-024-12651-6","journal-title":"BMC Cancer"},{"issue":"4","key":"11822_CR29","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/bloodadvances.2024013586","volume":"9","author":"G de Oliveira Canedo","year":"2025","unstructured":"de Oliveira Canedo G, Roddie C, Amrolia PJ (2025) Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. Blood Adv 9(4):704\u2013721. https:\/\/doi.org\/10.1182\/bloodadvances.2024013586","journal-title":"Blood Adv"},{"issue":"1","key":"11822_CR30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41408-024-01105-8","volume":"14","author":"L Wang","year":"2024","unstructured":"Wang L, Fang C, Kang Q, Huang W, Chen Z, Zhao W, Wang L, Wang Y, Tan K, Guo X, Xu Y, Wang S, Wang L, Qiao J, Tang Z, Yu C, Xu Y, Li Y, Yu L (2024) Bispecific CAR-T cells targeting CD19\/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I\/II trial. Blood Cancer J 14(1):130. https:\/\/doi.org\/10.1038\/s41408-024-01105-8","journal-title":"Blood Cancer J"},{"key":"11822_CR31","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","volume":"10","author":"X Xu","year":"2019","unstructured":"Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, Li M, Tu H, Liu Y, Tu S, Li Y (2019) Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. Front Immunol 10:2664. https:\/\/doi.org\/10.3389\/fimmu.2019.02664","journal-title":"Front Immunol"},{"issue":"22","key":"11822_CR32","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1182\/blood.v128.22.4066.4066","volume":"128","author":"A Alhammer","year":"2016","unstructured":"Alhammer A, Case M, Blair HJ, Vormoor J, Irving J (2016) Exploring Pre-B Cell Receptor Signalling As a Therapeutic Target in Acute Lymphoblastic Leukaemia. Blood 128(22):4066\u20134066. https:\/\/doi.org\/10.1182\/blood.v128.22.4066.4066","journal-title":"Blood"},{"issue":"4","key":"11822_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/modpathol.3800079","volume":"17","author":"N Kiyokawa","year":"2004","unstructured":"Kiyokawa N, Sekino T, Matsui T, Takenouchi H, Mimori K, Tang W-r, Matsui J, Taguchi T, Katagiri YU, Okita H, Matsuo Y, Karasuyama H, Fujimoto J (2004) Diagnostic importance of CD179a\/b as markers of precursor B-cell lymphoblastic lymphoma. Mod Pathol 17(4):423\u2013429. https:\/\/doi.org\/10.1038\/modpathol.3800079","journal-title":"Mod Pathol"},{"issue":"10","key":"11822_CR34","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2326-6066.cir-17-0171","volume":"5","author":"MP Velasquez","year":"2017","unstructured":"Velasquez MP, Szoor A, Vaidya A, Thakkar A, Nguyen P, Wu M-F, Liu H, Gottschalk S (2017) CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells. Cancer Immunol Res 5(10):860\u2013870. https:\/\/doi.org\/10.1158\/2326-6066.cir-17-0171","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"11822_CR35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/immu.200310020","volume":"33","author":"J Bukczynski","year":"2003","unstructured":"Bukczynski J, Wen T, Watts TH (2003) Costimulation of human CD28\u2009\u2013\u2009T cells by 4-1BB ligand. Eur J Immunol 33(2):446\u2013454. https:\/\/doi.org\/10.1002\/immu.200310020","journal-title":"Eur J Immunol"},{"issue":"13","key":"11822_CR36","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.ccr-18-2559","volume":"25","author":"E Drent","year":"2019","unstructured":"Drent E, Poels R, Ruiter R, van de Donk NWCJ, Zweegman S, Yuan H, de Bruijn J, Sadelain M, Lokhorst HM, Groen RWJ, Mutis T, Themeli M (2019) Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor\u2013engineered T Cells. Clin Cancer Res 25(13):4014\u20134025. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-2559","journal-title":"Clin Cancer Res"},{"issue":"2","key":"11822_CR37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/mt.2009.210","volume":"18","author":"X-S Zhong","year":"2010","unstructured":"Zhong X-S, Matsushita M, Plotkin J, Riviere I, Sadelain M (2010) Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase\/AKT\/Bcl-XL Activation and CD8\u2009+\u2009T Cell\u2013mediated Tumor Eradication. Mol Ther 18(2):413\u2013420. https:\/\/doi.org\/10.1038\/mt.2009.210","journal-title":"Mol Ther"},{"issue":"1","key":"11822_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","volume":"56","author":"R Singh","year":"2024","unstructured":"Singh R, Kim Y-H, Lee S-J, Eom H-S, Choi BK (2024) 4-1BB immunotherapy: advances and hurdles. Exp Mol Med 56(1):32\u201339. https:\/\/doi.org\/10.1038\/s12276-023-01136-4","journal-title":"Exp Mol Med"},{"key":"11822_CR39","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","volume":"18","author":"X Zhao","year":"2020","unstructured":"Zhao X, Yang J, Zhang X, Lu X-A, Xiong M, Zhang J, Zhou X, Qi F, He T, Ding Y, Hu X, De Smet F, Lu P, Huang X (2020) Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia. Mol Therapy - Oncolytics 18:272\u2013281. https:\/\/doi.org\/10.1016\/j.omto.2020.06.016","journal-title":"Mol Therapy - Oncolytics"},{"key":"11822_CR40","doi-asserted-by":"publisher","first-page":"947648","DOI":"10.3389\/fimmu.2022.947648","volume":"13","author":"CRF Silveira","year":"2022","unstructured":"Silveira CRF, Corveloni AC, Caruso SR, Mac\u00eado NA, Brussolo NM, Haddad F, Fernandes TR, de Andrade PV, Orellana MD, Guerino-Cunha RL (2022) Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications. Front Immunol 13:947648. https:\/\/doi.org\/10.3389\/fimmu.2022.947648","journal-title":"Front Immunol"},{"issue":"1","key":"11822_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s10238-024-01442-9","volume":"24","author":"M Rehman","year":"2024","unstructured":"Rehman M, Qaiser A, Khan HS, Manzoor S, Ashraf J (2024) Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy. Clin Experimental Med 24(1):180. https:\/\/doi.org\/10.1007\/s10238-024-01442-9","journal-title":"Clin Experimental Med"},{"issue":"2","key":"11822_CR42","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1182\/bloodadvances.2021005245","volume":"6","author":"SS Winter","year":"2022","unstructured":"Winter SS, McCaustland A, Qu C, Simeona N, Heerema NA, Carroll AJ, Wood BL, Gheorghe G, Mullighan CG, Wilson BS (2022) VpreB surrogate light chain expression in B-lineage ALL: a report from the Children\u2019s Oncology Group. Blood Adv 6(2):585\u2013589. https:\/\/doi.org\/10.1182\/bloodadvances.2021005245","journal-title":"Blood Adv"},{"issue":"1","key":"11822_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/ijms25010010","volume":"25","author":"A Tkachenko","year":"2024","unstructured":"Tkachenko A, Kupcova K, Havranek O (2024) B-Cell Receptor Signaling and Beyond: The Role of Ig\u03b1 (CD79a)\/Ig\u03b2 (CD79b) in Normal and Malignant B Cells. Int J Mol Sci 25(1):10. https:\/\/doi.org\/10.3390\/ijms25010010","journal-title":"Int J Mol Sci"},{"key":"11822_CR44","doi-asserted-by":"publisher","unstructured":"Rasaiyaah J, Georgiadis C, Preece R, Mock U, Qasim W (2018) TCR\u03b1\u03b2\/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. JCI insight 3(13). https:\/\/doi.org\/10.1172\/jci.insight.99442","DOI":"10.1172\/jci.insight.99442"},{"issue":"5","key":"11822_CR45","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.apsb.2020.10.020","volume":"11","author":"H Dana","year":"2021","unstructured":"Dana H, Chalbatani GM, Jalali SA, Mirzaei HR, Grupp SA, Suarez ER, Rap\u00f4so C, Webster TJ (2021) CAR-T cells: Early successes in blood cancer and challenges in solid tumors. Acta Pharm Sinica B 11(5):1129\u20131147. https:\/\/doi.org\/10.1016\/j.apsb.2020.10.020","journal-title":"Acta Pharm Sinica B"},{"key":"11822_CR46","doi-asserted-by":"publisher","unstructured":"Dourthe ME, Baruchel A (2021) CAR T-cells in acute lymphoblastic leukemia: Current results. Bull Cancer 108(10). https:\/\/doi.org\/10.1016\/j.bulcan.2021.08.001. Supplement):S40-S54","DOI":"10.1016\/j.bulcan.2021.08.001"},{"issue":"7","key":"11822_CR47","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.3390\/ijms24076300","volume":"24","author":"RC De Marco","year":"2023","unstructured":"De Marco RC, Monzo HJ, Ojala PM (2023) CAR T Cell Therapy: A Versatile Living Drug. IJMS 24(7):6300. https:\/\/doi.org\/10.3390\/ijms24076300","journal-title":"IJMS"},{"issue":"21","key":"11822_CR48","doi-asserted-by":"publisher","first-page":"15688","DOI":"10.3390\/ijms242115688","volume":"24","author":"AC Uscanga-Palomeque","year":"2023","unstructured":"Uscanga-Palomeque AC, Ch\u00e1vez-Escamilla AK, Alvizo-B\u00e1ez CA, Saavedra-Alonso S, Terrazas-Armend\u00e1riz LD, Tamez-Guerra RS, Rodr\u00edguez-Padilla C, Alcocer-Gonz\u00e1lez JM (2023) CAR-T Cell Therapy: From the Shop to Cancer Therapy. IJMS 24(21):15688. https:\/\/doi.org\/10.3390\/ijms242115688","journal-title":"IJMS"},{"issue":"4","key":"11822_CR49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7","journal-title":"Blood Cancer J"},{"key":"11822_CR50","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","volume":"106","author":"TA Bui","year":"2024","unstructured":"Bui TA, Mei H, Sang R, Ortega DG, Deng W (2024) Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. eBioMedicine 106:105266. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105266","journal-title":"eBioMedicine"},{"issue":"7","key":"11822_CR51","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00262-023-03422-6","volume":"72","author":"J Cheng","year":"2023","unstructured":"Cheng J, Ge T, Zhu X, Wang J, Zeng Y, Mu W, Cai H, Dai Z, Jin J, Yang Y, Hu G, Mao X, Zhou J, Zhu L, Huang L (2023) Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia. Cancer Immunol Immunother 72(7):2331\u20132346. https:\/\/doi.org\/10.1007\/s00262-023-03422-6","journal-title":"Cancer Immunol Immunother"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11822-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11822-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11822-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:16Z","timestamp":1777374976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11822-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11822"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11822-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Research Ethics Committee at the Faculty of Medicine, Ain Shams University, approval No: FMASU R25\/2024. Informed consent was obtained from all participants prior to their involvement in the study. The study was performed following all relevant ethical standards of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval<!--Emphasis Type='Bold' removed-->and consent for participation"}},{"value":"The protocol and procedures used in this study were reviewed and approved by the Committee for the Care and Use of Laboratory Animals (CICUAL) of Ain Shams Medical Research Institute Animal Care, Faculty of Medicine, Ain Shams University, under approval number RE (369) 24. All experimental procedures followed the international guidelines for the care and use of laboratory animals.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal ethics approval"}},{"value":"The authors declare no conflicts of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}}],"article-number":"682"}}